Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12344204 | 0.76 | — | — | |
| SCHEMBL4237982 | 0.75 | — | — | |
| SCHEMBL3372234 | 0.72 | — | — | |
| SCHEMBL11578183 | 0.72 | PDE10A (0.36) | ALDH1A1TRPM8 | |
| SCHEMBL11427298 | 0.71 | — | — | |
| SCHEMBL28497778 | 0.71 | — | — | |
| SCHEMBL19019998 | 0.69 | ECE1 (0.44) | ALDH1A1TP53SMN1; SMN2ALOX5 | |
| SCHEMBL7099239 | 0.68 | NUDT1 (0.32) | — | |
| SCHEMBL2642561 | 0.67 | — | — | |
| SCHEMBL216359 | 0.67 | PDE2A (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 273 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030064929-A1 | Modulating body/cranial hair growth | DURANTON ALBERT (FR) | 2003-04-03 | — | — | US | claimed |
| EP-0648488-B1 | Method to alter hairgrowth and compositions therefor | OREAL (FR) | 2000-11-29 | — | — | EP | claimed |
| US-5928654-A | Modulating body/cranial hair growth with lipoxygenase/cyclooxygenase inhibitors | SOCIETE L'OREAL S.A. (FR) | 1999-07-27 | — | — | US | claimed |
| EP-0800815-A2 | Use of at least one lypoxygenase inhibitor and at least one cyclo-oxygenase inhibitor to alter hair growth | L'OREAL (FR) | 1997-10-15 | — | — | EP | claimed |
| EP-0648488-A1 | Method to alter hairgrowth and compositions therefor | L'OREAL (FR) | 1995-04-19 | — | — | EP | claimed |
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| US-20240190981-A1 | Humanized Anti-CD70 Binding Agents and Uses Thereof | SEAGEN INC (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240182580-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | SUTRO BIOPHARMA INC (US) | 2024-06-06 | — | — | US | disclosed |
| WO-2024091979-A1 | CD276 (B7-H3) ANTIBODY-DRUG CONJUGATES | BRICKBIO, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-11958909-B2 | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use | SUTRO BIOPHARMA, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| EP-3488870-B1 | ANTI-CD70 ANTIBODY DRUG CONJUGATES | AMBRX INC (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20240084031-A1 | VARIANT TARGET BINDING AGENTS AND USES THEREOF | SEAGEN INC. (US) | 2024-03-14 | — | — | US | disclosed |
| WO-2004032828-A2 | ANTI-CD20 ANTIBODY-DRUG CONJUGATES FOR THE TREATMENT OF CANCER AND IMMUNE DISORDERS | SEATTLE GENETICS, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
| WO-2003043583-A2 | TREATMENT OF IMMUNOLOGICAL DISORDERS USING ANTI-CD30 ANTIBODIES | SEATTLE GENETICS, INC. (US) | 2003-05-30 | — | — | WO | disclosed |
| US-20030064929-A1 | Modulating body/cranial hair growth | DURANTON ALBERT (FR) | 2003-04-03 | — | — | US | disclosed |
| US-6465421-B1 | PROMOTING THE GROWTH OF BODY AND/OR HEAD HAIR AND/OR COMBATTING THE LOSS OF SUCH HAIR VIA CYCLOOXYGENASE TREATMENT, AS WELL AS, CONTRARIWISE, RETARDING AND/OR PREVENTING THE GROWTH OF BODY/CRANIAL HAIR VIA LIPOXYGENASE TREATMENT | SOCIETE L'OREAL S.A. (FR) | 2002-10-15 | — | — | US | disclosed |
| EP-0648488-B1 | Method to alter hairgrowth and compositions therefor | OREAL (FR) | 2000-11-29 | — | — | EP | disclosed |
| US-5928654-A | Modulating body/cranial hair growth with lipoxygenase/cyclooxygenase inhibitors | SOCIETE L'OREAL S.A. (FR) | 1999-07-27 | — | — | US | disclosed |
| EP-0800815-A2 | Use of at least one lypoxygenase inhibitor and at least one cyclo-oxygenase inhibitor to alter hair growth | L'OREAL (FR) | 1997-10-15 | — | — | EP | disclosed |
| EP-0648488-A1 | Method to alter hairgrowth and compositions therefor | L'OREAL (FR) | 1995-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | CD74, CD63, CD47 | ALDH1A1 868/4885CYP3A4 2276/4885TP53 559/4885 |
| US-20240084031-A1 | VARIANT TARGET BINDING AGENTS AND USES THEREOF | CD74, CD2BP2, TSG101 | ALDH1A1 3624/4885CYP3A4 3830/4885TP53 17/4885 |
| US-20240182580-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | CD74, CD63, CD99 | ALDH1A1 1241/4885CYP3A4 2755/4885TP53 253/4885 |
| US-11958909-B2 | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use | DNPEP, LNPEP, ANPEP | ALDH1A1 4661/4885CYP3A4 4840/4885TP53 794/4885 |
| US-20030064929-A1 | Modulating body/cranial hair growth | ALOX15B, ALOX12, ALOX5 | ALDH1A1 422/4885CYP3A4 2023/4885TP53 3951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.